Luminex (LMNX) 10-Q 5 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 04, 2013
Entity [Abstract]	'	'
Entity Registrant Name	'Luminex Corp	'
Entity Central Index Key	'0001033905	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	41,868,338
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$57,169	$42,789
Short-term investments	5,497	13,607
Accounts receivable, net	30,210	33,273
Inventories, net	29,742	29,937
Deferred income taxes	1,603	4,783
Prepaids and other	5,749	4,388
Total current assets	129,970	128,777
Property and equipment, net	32,788	26,229
Intangible assets, net	61,320	65,218
Deferred income taxes	14,462	14,360
Long-term investments	0	3,000
Goodwill	50,853	51,128
Other	4,503	8,463
Total assets	293,896	297,175
Current liabilities:	'	'
Accounts payable	9,038	9,650
Accrued liabilities	11,756	12,866
Deferred revenue	4,949	4,134
Current portion of long-term debt	924	1,138
Total current liabilities	26,667	27,788
Long-term debt	788	1,702
Deferred revenue	2,508	2,933
Other	5,038	5,085
Total liabilities	35,001	37,508
Stockholders' equity:	'	'
Common stock, $.001 par value, 200,000,000 shares authorized; issued and outstanding: 41,043,801 shares at September 30, 2013; 40,824,932 shares at December 31, 2012	41	41
Preferred stock, $.001 par value, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Additional paid-in capital	291,156	293,392
Accumulated other comprehensive income	585	1,101
Accumulated deficit	-32,887	-34,867
Total stockholders' equity	258,895	259,667
Total liabilities and stockholders' equity	$293,896	$297,175

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS Parenthetical (USD $)	Sep. 30, 2013	Dec. 31, 2012
Stockholders' equity:	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, issued (in shares)	41,043,801	40,824,932
Common stock, outstanding (in shares)	41,043,801	40,824,932
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]	'	'	'	'
Revenue	$50,780	$50,047	$158,267	$147,047
Cost of revenue	19,999	15,002	51,472	43,830
Gross profit	30,781	35,045	106,795	103,217
Operating expenses:	'	'	'	'
Research and development	10,346	11,186	34,852	31,467
Selling, general and administrative	21,466	19,462	67,429	53,075
Amortization of acquired intangible assets	1,021	1,030	3,077	3,214
Restructuring costs	2,142	0	2,142	0
Total operating expenses	34,975	31,678	107,500	87,756
(Loss) income from operations	-4,194	3,367	-705	15,461
Interest expense from long-term debt	-16	-40	-67	-162
Other income, net	6,638	25	6,730	124
Income before income taxes	2,428	3,352	5,958	15,423
Income taxes	-1,632	-1,676	-3,978	-7,268
Net income	796	1,676	1,980	8,155
Other comprehensive income:	'	'	'	'
Foreign currency translation adjustments	106	278	-515	208
Unrealized gain (loss) on available-for-sale securities, net of tax	1	-14	-1	-32
Other comprehensive income (loss)	107	264	-516	176
Comprehensive income	$903	$1,940	$1,464	$8,331
Net income per share, basic	$0.02	$0.04	$0.05	$0.20
Shares used in computing net income per share, basic	40,752	41,000	40,712	40,995
Net income per share, diluted	$0.02	$0.04	$0.05	$0.19
Shares used in computing net income per share, diluted	41,919	41,887	41,771	42,117

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net income	$796	$1,676	$1,980	$8,155
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'	'
Depreciation and amortization	3,994	3,613	11,747	10,668
Stock-based compensation	1,889	2,338	6,733	7,552
Deferred income tax expense	1,989	1,987	3,415	2,916
Excess income tax (benefit) expense from employee stock-based awards	-15	590	274	-2,183
Gain on sale of assets	-5,388	0	-5,305	0
Non-cash restructuring charges	3,695	0	3,695	0
Other	-34	472	-1,115	655
Changes in operating assets and liabilities:	'	'	'	'
Accounts receivable, net	1,384	-5,043	3,076	-8,226
Inventories, net	1,769	-877	-1,914	-2,604
Other assets	-415	-663	-2,058	-2,294
Accounts payable	2,215	1,637	-718	1,706
Accrued liabilities	-1,184	-792	-2,727	-2,007
Deferred revenue	439	-330	409	-237
Net cash provided by operating activities	11,134	4,608	17,492	14,101
Cash flows from investing activities:	'	'	'	'
Purchases of available-for-sale securities	-2,997	-2,994	-8,489	-13,489
Sales and maturities of available-for-sale securities	2,996	13,070	19,632	43,075
Purchase of property and equipment	-6,914	-2,152	-15,136	-7,509
Proceeds from sale of assets	9,533	0	9,564	0
Business acquisition consideration, net of cash acquired	0	-48,277	0	-48,277
Purchase of cost method investment	0	-1,000	0	-1,000
Acquired technology rights	0	-51	-930	-342
Net cash provided by (used in) investing activities	2,618	-41,404	4,641	-27,542
Cash flows from financing activities:	'	'	'	'
Payments on debt	0	0	-1,105	-1,025
Proceeds from issuance of common stock	5,973	861	7,891	3,224
Payments for stock repurchases	0	-11,036	-14,343	-20,916
Excess income tax benefit (expense) from employee stock-based awards	15	-590	-274	2,183
Net cash provided by (used in) financing activities	5,988	-10,765	-7,831	-16,534
Effect of foreign currency exchange rate on cash	-49	149	78	179
Change in cash and cash equivalents	19,691	-47,412	14,380	-29,796
Cash and cash equivalents, beginning of period	37,478	75,898	42,789	58,282
Cash and cash equivalents, end of period	$57,169	$28,486	$57,169	$28,486

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2013
BASIS OF PRESENTATION [Abstract]	'
BASIS OF PRESENTATION	'
	NOTE 1 — BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated financial statements have been prepared by Luminex Corporation (the “Company” or “Luminex”) in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information and the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring entries) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 (the "2012 10-K").
	The Company has two segments for financial reporting purposes: the technology and strategic partnerships (“TSP”) segment and the assays and related products (“ARP”) segment.  See Note 11 — Segment Information.
	The Company has reclassified certain 2012 amounts in the accompanying consolidated financial statements to conform to the 2013 presentation. These reclassifications include $0.5 million and $1.7 million of ARP segment selling, general and administrative expenses and the related headcount reclassified to ARP segment research and development expenses for the three and nine months ended September 30, 2012, respectively, and $3.0 million and $8.9 million of TSP segment selling, general and administrative expenses and the related headcount reclassified to ARP segment selling, general and administrative expenses for the three and nine months ended September 30, 2012, respectively. These reclassifications had no effect on the Company's consolidated comprehensive income or stockholders' equity.

RESTRUCTURING_RESTRUCTURING

RESTRUCTURING RESTRUCTURING	9 Months Ended
	Sep. 30, 2013
RESTRUCTURING [Abstract]	'
Restructuring and Related Activities Disclosure [Text Block]	'
	NOTE 2 — RESTRUCTURING
	In August 2013, the Company announced a restructuring plan focused on its ARP segment's Newborn Screening Group and its Brisbane, Australia office where automated punching systems are designed and manufactured. The Company is exploring strategic alternatives for its Newborn Screening assets and related automated punching group, including a potential sale or abandonment of that business. The Company has reviewed the requirements for held-for-sale and discontinued operations presentation and has determined that this business did not qualify for this presentation at September 30, 2013. The Company will continue selling its automated punching systems while it explores strategic alternatives for this business.
	The Company recorded total pre-tax restructuring charges of $4.3 million in the third quarter of 2013, which primarily consisted of the non-cash estimated impairment of inventory, intangible assets, property and equipment, together with employee separation costs. The Company measured and accrued the liabilities associated with employee separation costs at fair value as of the date the plan was announced and terminations were communicated to employees, which primarily included severance pay and other separation costs such as outplacement services and benefits. As a result of the organizational change, the Company eliminated approximately 5% of its workforce. In conjunction with the restructuring plan, the Company evaluated its tangible and intangible assets for estimated impairment and recorded non-cash impairment charges of $3.7 million in the third quarter of 2013. The Company determined the fair value of the assets based upon prices for similar assets.  See Note 7 — Goodwill and Other Intangible Assets.
	The Company will continue to review the remaining asset balances for possible further impairment until sale or abandonment. The Company will measure and accrue the facilities exit costs at fair value upon the Company's exit. Facilities exit costs will primarily consist of cease-use losses to be recorded upon vacating the facilities and fixed asset impairment.
	Statement of Operations	2013 Restructuring Plan
	Non-cash impairment charges:
	Inventory	$	2,015
	Property and equipment	980
	Intangible Assets	700
	Employee separation costs	598
	Facility exit costs	—
	Other	50
	Total charges	$	4,343
	Recorded to cost of revenue	2,201
	Recorded to restructuring costs	$	2,142
	Rollforward of Accrued Restructuring
	Total charges	$	4,343
	Non-cash impairment charges	(3,695		)
	Employee separation payments	(488		)
	Facility exit costs	—
	Foreign exchange and other adjustments	(50		)
	Balance at September 30, 2013	$	110
	The remaining restructuring accrual balance is expected to be paid within the next six months. As such, it is recorded as a current liability within accrued liabilities on the consolidated balance sheet as of September 30, 2013.

BUSINESS_COMBINATIONS

BUSINESS COMBINATIONS	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
BUSINESS COMBINATIONS	'
	NOTE 3 — BUSINESS COMBINATIONS
	On July 11, 2012, the Company completed its acquisition of GenturaDx, Inc., a British Virgin Islands corporation with operations in Hayward, California (“GenturaDx”). GenturaDx was a molecular diagnostics company in late stage development of a fully integrated, highly automated, real-time polymerase chain reaction ("PCR") system that employs a single-use cassette for sample-to-answer workflow. Under the terms of the acquisition agreement, the Company acquired all of the outstanding capital stock of GenturaDx in exchange for approximately $49.3 million cash consideration plus (i) $3.0 million in consideration contingent upon achieving certain future development and regulatory milestones by December 31, 2013, (ii) up to $7.0 million in consideration contingent upon achieving certain future development and regulatory milestones by June 30, 2014 and (iii) additional consideration contingent upon acquired products exceeding certain revenue thresholds in each of 2013, 2014 and 2015. Of the approximately $8.1 million that was deposited in escrow as security for potential indemnity claims and certain other expressly enumerated matters, approximately $6.0 million remains in escrow as of September 30, 2013. Additionally, up to 30% of the milestone payments are subject to certain set-off rights of the Company for indemnification claims under the acquisition agreement. The Company's acquisition of GenturaDx was funded with cash on hand.

INVESTMENTS

INVESTMENTS	9 Months Ended
	Sep. 30, 2013
Investments [Abstract]	'
INVESTMENTS	'
	NOTE 4 — INVESTMENTS
	Marketable Securities
	The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date.  Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings.  Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, which approximates the fair value of these investments.   Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale, and are carried at fair market value, with the unrealized gains and losses included in the determination of comprehensive income and reported in stockholders’ equity.  As of September 30, 2013 and December 31, 2012, all of the Company’s marketable securities were classified as available for sale.  Marketable securities are recorded as either short-term or long-term on the balance sheet based on the contractual maturity date.  The fair value of all securities is determined by quoted market prices, market interest rates inputs, or other than quoted prices that are observable either directly or indirectly (as of the end of the reporting period).  Declines in fair value below the Company’s carrying value deemed to be other than temporary are charged against net earnings.
	Available-for-sale securities consisted of the following as of September 30, 2013 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income			Estimated Fair Value
	Current:
	Money Market funds	$	36,311	$	—	$	—		$	36,311
	Non-government sponsored debt securities	5,498		—		(1		)	5,497
	Total current securities	41,809		—		(1		)	41,808
	Noncurrent:
	Non-government sponsored debt securities	—		—		—			—
	Total noncurrent securities	—		—		—			—
	Total available-for-sale securities	$	41,809	$	—	$	(1	)	$	41,808
	Available-for-sale securities consisted of the following as of December 31, 2012 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income			Estimated Fair Value
	Current:
	Money Market funds	$	16,987	$	—	$	—		$	16,987
	Non-government sponsored debt securities	13,602		5		—			13,607
	Total current securities	30,589		5		—			30,594
	Noncurrent:
	Non-government sponsored debt securities	3,000		—		—			3,000
	Total noncurrent securities	3,000		—		—			3,000
	Total available-for-sale securities	$	33,589	$	5	$	—		$	33,594
	There were no proceeds from the sales of available-for-sale securities during the three months ended September 30, 2013 or 2012. Realized gains and losses on sales of investments are determined using the specific identification method.  Realized gains and losses are included in other income (expense) in the Consolidated Statements of Comprehensive Income. Net unrealized holding losses on available-for-sale securities of $1,000, net of $0 of tax benefit, have been included in accumulated other comprehensive income as of September 30, 2013.  All of the Company’s available-for-sale securities with gross unrealized losses as of September 30, 2013 have been in a loss position for less than 12 months.
	The estimated fair value of available-for-sale debt securities at September 30, 2013 and December 31, 2012, by contractual maturity, was as follows (in thousands):
		Estimated Fair Value
		September 30, 2013		December 31, 2012
	Due in one year or less	$	5,497	$	13,607
	Due after one year through two years	—		3,000
		$	5,497	$	16,607
	Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.
	Non-Marketable Securities and Other-Than-Temporary Impairment
	As of September 30, 2013 the Company owned a minority interest in a private company based in the U.S., through its investment of $1.0 million in the company. This non-controlling, minority interest is included at cost in other long-term assets on the Company's Condensed Consolidated Balance Sheets as the Company does not have significant influence over the investee as the Company owns less than 20% of the voting equity in the investee and the investee is not publicly traded.
	A private company, that the Company had previously made a $4.1 million investment in, was acquired by a third party in July 2013 and, as a result, our non-controlling, minority interest in that private company was liquidated. We realized a gain of $5.4 million on the liquidation of this non-controlling, minority interest investment in the third quarter of 2013, which is recorded in other income on the Condensed Consolidated Statement of Comprehensive Income.
	The Company regularly evaluates the carrying value of these cost-method investments for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investments. The primary indicators the Company utilizes to identify these events and circumstances are the investees’ ability to remain in business, such as the investees’ liquidity and rate of cash use, and the investees’ ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is judged to be other-than-temporary, the Company will record an other-than-temporary impairment charge in other income, net in the Consolidated Statements of Comprehensive Income. As the inputs utilized for the Company's periodic impairment assessment are not based on observable market data, these cost method investments are classified within Level 3 of the fair value hierarchy. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, a cost method investment's fair value is not estimated as there are no identified events or changes in the circumstances that may have a significant adverse effect on the fair value of the investment and to do so would be impractical.

INVENTORY_NET

INVENTORY, NET	9 Months Ended
	Sep. 30, 2013
Inventory, Net [Abstract]	'
INVENTORIES, NET	'
	NOTE 5 — INVENTORIES, NET
	Inventories are stated at the lower of cost or market, with cost determined according to the standard cost method, which approximates the first-in, first-out method.  The Company routinely assesses its on-hand inventory for timely identification and measurement of obsolete, slow-moving or otherwise impaired inventory. Inventories consisted of the following (in thousands):
		September 30, 2013		December 31, 2012
	Parts and supplies	$	16,668	$	18,259
	Work-in-progress	5,928		4,831
	Finished goods	7,146		6,847
		$	29,742	$	29,937

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
FAIR VALUE MEASUREMENT	'
	NOTE 6 — FAIR VALUE MEASUREMENT
	The Fair Value Measurements and Disclosures Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The ASC describes a fair value hierarchy based on the following three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last unobservable:
	Level 1 –	Quoted prices in active markets for identical assets or liabilities.
	Level 2 –	Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 –	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company determines the fair value of its investment portfolio assets by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value.  There were no transfers between Level 1, Level 2, or Level 3 measurements for the three month period ended September 30, 2013.
	We record contingent consideration resulting from a business combination at its fair value on the acquisition date. The Company determines the fair value of the contingent consideration based primarily on the timing and probability of success of clinical events or regulatory approvals, the timing and probability of success of meeting commercial milestones, such as sales levels of a specific product, and discount rates. Our contingent consideration liability arose in connection with the GenturaDx acquisition. The Company re-evaluates its assumptions for its contingent consideration fair value determinations each quarter. Changes to the fair value of contingent consideration obligations can result from adjustments to discount rates, accretion of the discount rates due to the passage of time, changes in our estimates of the likelihood of or timing of achieving any development or commercial milestones, changes in the probability of certain clinical events or changes in the assumed probability associated with regulatory approval. As a result of changes in assumptions surrounding the probability of success of meeting the timing of commercial milestones contemplated in the GenturaDx acquisition agreement, the Company adjusted the contingent consideration liability related to the GenturaDx acquisition from $1.2 million as of June 30, 2013 to $0 as of September 30, 2013. The assumptions related to determining the value of contingent consideration include a significant amount of judgment, and any changes in the underlying estimates could have a material impact on the amount of contingent consideration expense recorded in any given period.
	As of September 30, 2013 and December 31, 2012 the fair value of the Company's long-term debt was approximately $1.5 million and $2.5 million, respectively. The Company’s long-term debt is classified as a Level 3 instrument and the Company has used a discounted cash flow (“DCF”) model to determine the estimated fair value for disclosure purposes as of September 30, 2013 and December 31, 2012, which does not equal its carrying value on the Condensed Consolidated Balance Sheets.  The assumptions used in preparing the DCF model include estimates for (i) the amount and timing of future interest and principal payments and (ii) the rate of return indicative of the investment risk in the ownership of the Technology Partnerships Canada ("TPC") debt.  In making these assumptions, the Company considered relevant factors including the likely timing of principal repayments and the probability of full repayment considering the timing of royalty payments based upon total revenue.
	The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2013 and December 31, 2012 (in thousands):
		Fair Value Measurements at September 30, 2013 Using
		Level 1			Level 2		Level 3		Total
	Assets:
	Money Market funds	$	36,311		$	—	$	—	$	36,311
	Non-government sponsored debt securities	—			5,497		—		5,497
	Liabilities:
	Contingent consideration	$	—		$	—	$	—	$	—
		Fair Value Measurements at December 31, 2012 Using
		Level 1			Level 2		Level 3		Total
	Assets:
	Money Market funds	$	16,987		$	—	$	—	$	16,987
	Non-government sponsored debt securities	—			16,607		—		16,607
	Liabilities:
	Contingent consideration	$	—		$	—	$	1,370	$	1,370
	Changes in financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the period were as follows (in thousands):
		September 30, 2013			December 31, 2012
	Balance at beginning of year	$	1,370		$	—
	Contingent consideration recorded at acquisition	—			1,370
	Fair value adjustments	(1,370		)	—
	Balance at end of period	$	—		$	1,370

GOODWILL_AND_OTHER_INTANGIBLE_

GOODWILL AND OTHER INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
GOODWILL AND OTHER INTANGIBLE ASSETS	'
	NOTE 7 — GOODWILL AND OTHER INTANGIBLE ASSETS
	On July 11, 2012, the Company completed its acquisition of GenturaDx.  As a result, the Company recorded approximately $8.3 million of goodwill and $40.1 million of other identifiable intangible assets. All of the Company's goodwill relates to one reporting unit, the ARP segment, for goodwill impairment testing  Goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise. No goodwill impairments were recorded in 2013 or 2012. This goodwill is not expected to be deductible for tax purposes.
	The changes in the carrying amount of the Company’s goodwill during the period are as follows (in thousands):
		September 30, 2013			December 31, 2012
	Balance at beginning of year	$	51,128		$	42,763
	Acquisition of GenturaDx	—			8,292
	Foreign currency translation adjustments	(275		)	73
	Balance at end of period	$	50,853		$	51,128
	The current in-process research and development projects are scheduled to be completed in 2014.  The estimated aggregate costs to complete these projects are between $7.0 and $10.0 million. The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives):
		Finite-lived									Indefinite-lived
		Technology, trade secrets and know-how			Customer lists and contracts			Other identifiable intangible assets			IP R&D			Total
	2012
	Balance at December 31, 2011	$	30,000		$	7,981		$	1,933		$	631		$	40,545
	Additions due to acquisition of GenturaDx	—			—			—			40,100			40,100
	Write-off of IP R&D projects	—			—			—			(118		)	(118		)
	Foreign currency translation adjustments	30			5			8			14			57
	Balance at December 31, 2012	30,030			7,986			1,941			40,627			80,584
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2011	(9,999		)	(768		)	(341		)	—			(11,108		)
	Amortization expense	(3,187		)	(790		)	(266		)	—			(4,243		)
	Foreign currency translation adjustments	(7		)	(2		)	(6		)	—			(15		)
	Accumulated amortization balance at December 31, 2012	(13,193		)	(1,560		)	(613		)	—			(15,366		)
	Net balance at December 31, 2012	$	16,837		$	6,426		$	1,328		$	40,627		$	65,218
	Weighted average life (in years)	10			11			9
	2013
	Balance at December 31, 2012	$	30,030		$	7,986		$	1,941		$	40,627		$	80,584
	Write-off / Impairment	(214		)	(7		)	(20		)	(459		)	$	(700	)
	Foreign currency translation adjustments	(105		)	(19		)	(29		)	(68		)	(221		)
	Balance at September 30, 2013	29,711			7,960			1,892			40,100			79,663
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2012	(13,193		)	(1,560		)	(613		)	—			(15,366		)
	Amortization expense	(2,381		)	(591		)	(105		)	—			(3,077		)
	Foreign currency translation adjustments	61			14			25			—			100
	Accumulated amortization balance at September 30, 2013	(15,513		)	(2,137		)	(693		)	—			(18,343		)
	Net balance at September 30, 2013	$	14,198		$	5,823		$	1,199		$	40,100		$	61,320
	Weighted average life (in years)	10			11			9
	The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands):
	2013 (three months)	$	1,019
	2014	3,917
	2015	3,232
	2016	3,100
	2017	2,144
	Thereafter	7,808
		21,220
	IP R&D	40,100
		$	61,320

OTHER_COMPREHENSIVE_LOSS_INCOM

OTHER COMPREHENSIVE (LOSS) INCOME	9 Months Ended
	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'
Comprehensive Income (Loss) Note	'
	NOTE 8 — OTHER COMPREHENSIVE (LOSS) INCOME
	Comprehensive (loss) income represents a measure of all changes in equity that result from recognized transactions and other economic events other than those resulting from investments by and distributions to shareholders. Other comprehensive (loss) income for the Company includes foreign currency translation adjustments and net unrealized holding gains and losses on available-for-sale investments.
	The following table presents the changes in each component of accumulated other comprehensive (loss) income, net of tax (in thousands):
		Foreign Currency Items			Available for Sale Investments			Accumulated Other Comprehensive Income Items
	Beginning balance, December 31, 2012	$	1,100		$	1		$	1,101
	Other comprehensive (loss) income before reclassifications	(515		)	8			(507		)
	Amounts reclassified from accumulated other comprehensive income	—			(9		)	(9		)
	Net current-period other comprehensive (loss)	(515		)	(1		)	(516		)
	Ending balance, September 30, 2013	$	585		$	—		$	585
	The following table presents the tax (expense) benefit allocated to each component of other comprehensive (loss) income (in thousands):
		Three Months Ended September 30, 2013									Nine Months Ended September 30, 2013
		Before Tax			Tax Benefit			Net of Tax			Before Tax			Tax Benefit		Net of Tax
	Foreign currency translation adjustments	$	106		$	—		$	106		$	(515	)	$	—	$	(515	)
	Unrealized (losses) gains on available-for-sale investments	1			—			1			(2		)	1		(1		)
	Other comprehensive (loss) income	$	107		$	—		$	107		$	(517	)	$	1	$	(516	)

EARNINGS_PER_SHARE

EARNINGS PER SHARE	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
EARNINGS PER SHARE	'
	NOTE 9 — EARNINGS PER SHARE
	A reconciliation of the denominators used in computing per share net income, or EPS, is as follows (in thousands, except per share amounts):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Numerator:
	Net income	$	796	$	1,676	$	1,980	$	8,155
	Denominator:
	Denominator for basic net income per share - weighted average common stock outstanding	40,752		41,000		40,712		40,995
	Effect of dilutive securities: stock options and awards	1,167		887		1,059		1,122
	Denominator for diluted net income per share - weighted average shares outstanding - diluted	41,919		41,887		41,771		42,117
	Basic net income per share	$	0.02	$	0.04	$	0.05	$	0.2
	Diluted net income per share	$	0.02	$	0.04	$	0.05	$	0.19
	Basic net (loss) income per share is computed by dividing the net (loss) income for the period by the weighted average number of common shares outstanding during the period. Diluted net (loss) income per share is computed by dividing the net (loss) income for the period by the weighted average number of common and common equivalent shares outstanding during the period.  Restricted stock (consisting of restricted stock awards, or RSAs, and restricted stock units, or RSUs) and stock options to acquire approximately 0.2 million and 0.2 million shares for the three months ended September 30, 2013 and 2012, respectively, and 0.2 million and 0.2 million shares for the nine months ended September 30, 2013 and 2012, respectively, were excluded from the computations of diluted EPS because the effect of including those RSAs, RSUs, and stock options would have been anti-dilutive.

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
STOCK-BASED COMPENSATION	'
	NOTE 10 — STOCK-BASED COMPENSATION
	The Company’s stock option activity for the nine months ended September 30, 2013 was as follows:
	Stock Options (shares in thousands)	Shares		Weighted Average Exercise Price
	Outstanding at December 31, 2012	1,676		$	12.13
	Granted	159		17.24
	Exercised	(798	)	8.84
	Cancelled or expired	(20	)	19
	Outstanding at September 30, 2013	1,017		$	15.37
	The Company had $2.3 million of total unrecognized compensation costs related to stock options at September 30, 2013 that are expected to be recognized over a weighted average period of 1.9 years.
	The Company’s restricted share activity for the nine months ended September 30, 2013 was as follows:
	Restricted Stock Awards (shares in thousands)	Shares		Weighted Average Grant Price
	Non-vested at December 31, 2012	818		$	19.32
	Granted	354		17.28
	Vested	(265	)	18.83
	Cancelled or expired	(55	)	19.41
	Non-vested at September 30, 2013	852		$	18.62
	Restricted Stock Units (in thousands)	Shares
	Non-vested at December 31, 2012	875
	Granted	193
	Vested	(77	)
	Cancelled or expired	(155	)
	Non-vested at September 30, 2013	836
	As of September 30, 2013, there was $15.1 million and $5.3 million of unrecognized compensation cost related to RSAs and RSUs, respectively. That cost is expected to be recognized over a weighted average period of 3.2 years for the RSAs and 2.2 years for the RSUs. The Company issues a small number of cash settled restricted stock units pursuant to the Company's equity incentive plan in certain foreign countries. These grants do not result in the issuance of common stock and are considered immaterial by the Company.
	The following are the stock-based compensation costs recognized in the Company’s condensed consolidated statements of comprehensive income (in thousands):
		Three Months Ended September 30,					Nine Months Ended September 30,
		2013			2012		2013		2012
	Cost of revenue	$	233		$	222	$	635	$	697
	Research and development	675			520		1,892		1,507
	Selling, general and administrative	981			1,596		4,206		5,348
	Stock-based compensation costs reflected in net income	$	1,889		$	2,338	$	6,733	$	7,552

SEGMENT_INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
SEGMENT INFORMATION	'
	NOTE 11 — SEGMENT INFORMATION
	Management has determined that the Company has two segments for financial reporting purposes:  the TSP segment and the ARP segment.  The accounting principles of the segments are the same as those described in the Summary of Significant Accounting Policies in the 2012 10-K.
	Intersegment sales are recorded at fixed prices that approximate the prices charged to third party strategic partners and are not a measure of segment operating earnings. Intersegment sales of approximately $2.2 million and $2.5 million for the quarters ending September 30, 2013 and 2012, and $7.9 million and $8.2 million for the nine months ended September 30, 2013 and 2012, respectively, have been eliminated upon consolidation.  The following is selected segment information for the periods indicated (in thousands):
		Three Months Ended September 30, 2013								Three Months Ended September 30, 2012
		TSP Segment		ARP Segment			Consolidated			TSP Segment		ARP Segment			Consolidated
	Revenues from external customers	$	33,335	$	17,445		$	50,780		$	31,584	$	18,463		$	50,047
	Depreciation and amortization	2,087		1,907			$	3,994		1,801		1,812			$	3,613
	Operating profit (loss)	9,293		(13,487		)	$	(4,194	)	7,205		(3,838		)	$	3,367
	Segment assets	187,422		106,474			$	293,896		166,763		115,742			$	282,505
		Nine Months Ended September 30, 2013								Nine Months Ended September 30, 2012
		TSP Segment		ARP Segment			Consolidated			TSP Segment		ARP Segment			Consolidated
	Revenues from external customers	$	96,352	$	61,915		$	158,267		$	91,358	$	55,689		$	147,047
	Depreciation and amortization	5,826		5,921			$	11,747		5,096		5,572			$	10,668
	Operating profit (loss)	23,368		(24,073		)	$	(705	)	21,725		(6,264		)	$	15,461
	Segment assets	187,422		106,474			$	293,896		166,763		115,742			$	282,505

ACCRUED_WARRANTY_COSTS

ACCRUED WARRANTY COSTS	9 Months Ended
	Sep. 30, 2013
Product Warranties Disclosures [Abstract]	'
ACCRUED WARRANTY COSTS	'
	NOTE 12 — ACCRUED WARRANTY COSTS
	Sales of certain of the Company's systems are subject to a warranty.  System warranties typically extend for a period of 12 months from the date of installation not to exceed 24 months from the date of shipment.  The Company estimates the amount of warranty claims on sold products that may be incurred based on current and historical data.  The actual warranty expense could differ from the estimates made by the Company based on product performance.  Warranty expenses are evaluated and adjusted periodically.
	The following table summarizes the changes in the warranty accrual (in thousands):
	Accrued warranty costs at December 31, 2012	$	603
	Warranty expenses	(783		)
	Accrual for warranty costs	1,163
	Accrued warranty costs at September 30, 2013	$	983

INCOME_TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	NOTE 13 — INCOME TAXES
	At the end of each interim reporting period, an estimate is made of the effective tax rate expected to be applicable for the full year.  The estimated full year’s effective tax rate is used to determine the income tax rate for each applicable interim reporting period.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date. The effective tax rate for the nine months ended September 30, 2013 was 66.77%, including amounts recorded for discrete events such as the effect of the retroactive extension of the U.S. research credit under the 2012 Taxpayer Relief Act. This differs from the statutory rate of 35% primarily because of the worldwide mix of consolidated earnings and losses before taxes and an assessment regarding the realizability of the Company’s deferred tax assets.  The Company’s tax expense reflects the full federal, various state, and foreign blended statutory rates.  The Company is utilizing its net operating losses in the U.S. and Canada; therefore cash taxes to be paid are expected to be in the range of 15%-20% of book tax expense.
	The Company or one of its subsidiaries files income tax returns in the U.S. federal jurisdiction, Australia, Canada, China, Japan, the Netherlands, and various states.  Due to net operating losses, the U.S., Canadian and Australian tax returns dating back to 2000, 2005, and 2010, respectively, can still be reviewed by the taxing authorities.  The Company recorded liabilities of $121,000 associated with its uncertain tax positions in the third quarter of 2013.  No other material changes to this liability are expected within the next 12 months.  For the nine months ended September 30, 2013, there were no material changes to the total amount of unrecognized tax benefits.  The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 14 - COMMITMENTS AND CONTINGENCIES
	On August 30, 2012 Abbott Laboratories, Inc. ("Abbott") was named as a defendant in the complaint filed by ENZO Life Sciences, Inc. ("ENZO") in the U.S. District Court in Delaware for alleged infringement of its US Patent 7,064,197 as a result of Abbott's distribution of the Company's xTAG Respiratory Viral Panel.  The Company and Abbott have entered into an agreement requiring the Company to defend and indemnify Abbott for any alleged patent infringement resulting from its distribution of the Company's Respiratory Viral Panel. The complaint seeks unspecified monetary damages and injunctive relief. Abbott filed an answer to the complaint on October 15, 2012.  On November 30, 2012, the Company intervened in the lawsuit. On January 2, 2013, ENZO filed additional claims against the Company, alleging infringement of US Patent 7,064,197 resulting from the Company's sale of its xTAG, FlexScript LDA, SelecTAG, and xMAP Salmonella Serotyping Assay products and alleging infringement of US Patent 8,097,405 resulting from the Company's sale of Multicode products.  The Company filed an answer to ENZO's additional claims on January 28, 2013.  On October 2, 2013 ENZO filed additional claims against the Company, alleging infringement of U.S. Patent 6,992,180 resulting from the Company’s sale of Multicode products.  The Company filed an answer to ENZO’s additional claims on October 21, 2013. A trial date has not been set. The parties to the lawsuit have engaged in the discovery process.
	When and if it appears probable in management's judgment that the Company would incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, liabilities will be recorded in the financial statements and charges will be recorded against earnings.  There can be no assurance that the Company will successfully defend this suit or that a judgment against us would not materially adversely affect our financial condition or operating results.
	In January 2013, the Company finalized the termination of its molecular diagnostics distribution agreements and an expense of $7.0 million was recorded in selling, general and administrative expenses in the first quarter of 2013. All payments were made in the second quarter of 2013.

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2013
Recent Accounting Pronouncements [Abstract]	'
RECENT ACCOUNTING PRONOUNCEMENTS	'
	NOTE 15 — RECENT ACCOUNTING PRONOUNCEMENTS
	In February 2013, the FASB issued guidance on disclosures of additional information with respect to changes in accumulated other comprehensive income ("AOCI") balances by component and significant items reclassified out of AOCI. Expanded disclosures for presentation of changes in AOCI involve disaggregating the total change of each component of other comprehensive income as well as presenting separately for each such component the portion of the change in AOCI related to (1) amounts reclassified into income and (2) current-period other comprehensive income. Additionally, for amounts reclassified into income, disclosure in one location would be required, based upon each specific AOCI component, of the amounts impacting individual income statement line items. Disclosure of the income statement line item impacts will be required only for components of AOCI reclassified into income in their entirety. The disclosures required with respect to income statement line item impacts would be made in either the notes to the consolidated financial statements or parenthetically on the face of the financial statements. For the Company, this Accounting Standards Update is effective beginning January 1, 2013. Because this standard only impacts presentation and disclosure requirements, its adoption did not have a material impact on the Company's consolidated results of operations or financial condition.
	In July 2013, the FASB issued guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance requires an entity to present unrecognized tax benefits as a reduction to deferred tax assets when a net operating loss carryforward, similar tax loss or a tax credit carryforward exists, with limited exceptions. For the Company, this Accounting Standards Update is effective for fiscal years beginning on or after December 15, 2013, and for interim periods within those fiscal years. This pronouncement will have no effect on the financial statements as the Company has historically presented uncertain tax positions in accordance with this Accounting Standards Update.

RESTRUCTURING_RESTRUCTURING_Ta

RESTRUCTURING RESTRUCTURING (Tables)	9 Months Ended
	Sep. 30, 2013
RESTRUCTURING [Abstract]	'
Restructuring and Related Costs [Table Text Block]	'
	Statement of Operations	2013 Restructuring Plan
	Non-cash impairment charges:
	Inventory	$	2,015
	Property and equipment	980
	Intangible Assets	700
	Employee separation costs	598
	Facility exit costs	—
	Other	50
	Total charges	$	4,343
	Recorded to cost of revenue	2,201
	Recorded to restructuring costs	$	2,142
	Rollforward of Accrued Restructuring
	Total charges	$	4,343
	Non-cash impairment charges	(3,695		)
	Employee separation payments	(488		)
	Facility exit costs	—
	Foreign exchange and other adjustments	(50		)
	Balance at September 30, 2013	$	110
	The remaining restructuring accrual balance is expected to be paid within the next six months. As such, it is recorded as a current liability within accrued liabilities on the consolidated balance sheet as of September 30, 2013.

INVESTMENTS_Tables

INVESTMENTS (Tables)	9 Months Ended
	Sep. 30, 2013
Investments [Abstract]	'
Components of available-for-sale securities	'
	Available-for-sale securities consisted of the following as of September 30, 2013 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income			Estimated Fair Value
	Current:
	Money Market funds	$	36,311	$	—	$	—		$	36,311
	Non-government sponsored debt securities	5,498		—		(1		)	5,497
	Total current securities	41,809		—		(1		)	41,808
	Noncurrent:
	Non-government sponsored debt securities	—		—		—			—
	Total noncurrent securities	—		—		—			—
	Total available-for-sale securities	$	41,809	$	—	$	(1	)	$	41,808
	Available-for-sale securities consisted of the following as of December 31, 2012 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income			Estimated Fair Value
	Current:
	Money Market funds	$	16,987	$	—	$	—		$	16,987
	Non-government sponsored debt securities	13,602		5		—			13,607
	Total current securities	30,589		5		—			30,594
	Noncurrent:
	Non-government sponsored debt securities	3,000		—		—			3,000
	Total noncurrent securities	3,000		—		—			3,000
	Total available-for-sale securities	$	33,589	$	5	$	—		$	33,594
Estimated fair value of available-for-sale debt securities, by contractual maturity	'
	The estimated fair value of available-for-sale debt securities at September 30, 2013 and December 31, 2012, by contractual maturity, was as follows (in thousands):
		Estimated Fair Value
		September 30, 2013		December 31, 2012
	Due in one year or less	$	5,497	$	13,607
	Due after one year through two years	—		3,000
		$	5,497	$	16,607

INVENTORY_NET_Tables

INVENTORY, NET (Tables)	9 Months Ended
	Sep. 30, 2013
Inventory, Net [Abstract]	'
Schedule of Inventory, Current	'
	Inventories consisted of the following (in thousands):
		September 30, 2013		December 31, 2012
	Parts and supplies	$	16,668	$	18,259
	Work-in-progress	5,928		4,831
	Finished goods	7,146		6,847
		$	29,742	$	29,937

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair value, financial assets (cash equivalents and investments) measured on a recurring basis	'
	The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2013 and December 31, 2012 (in thousands):
		Fair Value Measurements at September 30, 2013 Using
		Level 1			Level 2		Level 3		Total
	Assets:
	Money Market funds	$	36,311		$	—	$	—	$	36,311
	Non-government sponsored debt securities	—			5,497		—		5,497
	Liabilities:
	Contingent consideration	$	—		$	—	$	—	$	—
		Fair Value Measurements at December 31, 2012 Using
		Level 1			Level 2		Level 3		Total
	Assets:
	Money Market funds	$	16,987		$	—	$	—	$	16,987
	Non-government sponsored debt securities	—			16,607		—		16,607
	Liabilities:
	Contingent consideration	$	—		$	—	$	1,370	$	1,370
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation	'
	Changes in financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the period were as follows (in thousands):
		September 30, 2013			December 31, 2012
	Balance at beginning of year	$	1,370		$	—
	Contingent consideration recorded at acquisition	—			1,370
	Fair value adjustments	(1,370		)	—
	Balance at end of period	$	—		$	1,370

GOODWILL_AND_OTHER_INTANGIBLE_1

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Changes in the carrying amount of goodwill	'
	The changes in the carrying amount of the Company’s goodwill during the period are as follows (in thousands):
		September 30, 2013			December 31, 2012
	Balance at beginning of year	$	51,128		$	42,763
	Acquisition of GenturaDx	—			8,292
	Foreign currency translation adjustments	(275		)	73
	Balance at end of period	$	50,853		$	51,128
Schedule of intangible assets	'
	The current in-process research and development projects are scheduled to be completed in 2014.  The estimated aggregate costs to complete these projects are between $7.0 and $10.0 million. The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives):
		Finite-lived									Indefinite-lived
		Technology, trade secrets and know-how			Customer lists and contracts			Other identifiable intangible assets			IP R&D			Total
	2012
	Balance at December 31, 2011	$	30,000		$	7,981		$	1,933		$	631		$	40,545
	Additions due to acquisition of GenturaDx	—			—			—			40,100			40,100
	Write-off of IP R&D projects	—			—			—			(118		)	(118		)
	Foreign currency translation adjustments	30			5			8			14			57
	Balance at December 31, 2012	30,030			7,986			1,941			40,627			80,584
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2011	(9,999		)	(768		)	(341		)	—			(11,108		)
	Amortization expense	(3,187		)	(790		)	(266		)	—			(4,243		)
	Foreign currency translation adjustments	(7		)	(2		)	(6		)	—			(15		)
	Accumulated amortization balance at December 31, 2012	(13,193		)	(1,560		)	(613		)	—			(15,366		)
	Net balance at December 31, 2012	$	16,837		$	6,426		$	1,328		$	40,627		$	65,218
	Weighted average life (in years)	10			11			9
	2013
	Balance at December 31, 2012	$	30,030		$	7,986		$	1,941		$	40,627		$	80,584
	Write-off / Impairment	(214		)	(7		)	(20		)	(459		)	$	(700	)
	Foreign currency translation adjustments	(105		)	(19		)	(29		)	(68		)	(221		)
	Balance at September 30, 2013	29,711			7,960			1,892			40,100			79,663
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2012	(13,193		)	(1,560		)	(613		)	—			(15,366		)
	Amortization expense	(2,381		)	(591		)	(105		)	—			(3,077		)
	Foreign currency translation adjustments	61			14			25			—			100
	Accumulated amortization balance at September 30, 2013	(15,513		)	(2,137		)	(693		)	—			(18,343		)
	Net balance at September 30, 2013	$	14,198		$	5,823		$	1,199		$	40,100		$	61,320
	Weighted average life (in years)	10			11			9
Estimated aggregate amortization expense for the next five years and thereafter	'
	The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands):
	2013 (three months)	$	1,019
	2014	3,917
	2015	3,232
	2016	3,100
	2017	2,144
	Thereafter	7,808
		21,220
	IP R&D	40,100
		$	61,320

OTHER_COMPREHENSIVE_LOSS_INCOM1

OTHER COMPREHENSIVE (LOSS) INCOME (Tables)	9 Months Ended
	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss)	'
	The following table presents the changes in each component of accumulated other comprehensive (loss) income, net of tax (in thousands):
		Foreign Currency Items			Available for Sale Investments			Accumulated Other Comprehensive Income Items
	Beginning balance, December 31, 2012	$	1,100		$	1		$	1,101
	Other comprehensive (loss) income before reclassifications	(515		)	8			(507		)
	Amounts reclassified from accumulated other comprehensive income	—			(9		)	(9		)
	Net current-period other comprehensive (loss)	(515		)	(1		)	(516		)
	Ending balance, September 30, 2013	$	585		$	—		$	585
Schedule of Comprehensive Income (Loss)	'
	The following table presents the tax (expense) benefit allocated to each component of other comprehensive (loss) income (in thousands):
		Three Months Ended September 30, 2013									Nine Months Ended September 30, 2013
		Before Tax			Tax Benefit			Net of Tax			Before Tax			Tax Benefit		Net of Tax
	Foreign currency translation adjustments	$	106		$	—		$	106		$	(515	)	$	—	$	(515	)
	Unrealized (losses) gains on available-for-sale investments	1			—			1			(2		)	1		(1		)
	Other comprehensive (loss) income	$	107		$	—		$	107		$	(517	)	$	1	$	(516	)

EARNINGS_PER_SHARE_Tables

EARNINGS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	'
	A reconciliation of the denominators used in computing per share net income, or EPS, is as follows (in thousands, except per share amounts):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Numerator:
	Net income	$	796	$	1,676	$	1,980	$	8,155
	Denominator:
	Denominator for basic net income per share - weighted average common stock outstanding	40,752		41,000		40,712		40,995
	Effect of dilutive securities: stock options and awards	1,167		887		1,059		1,122
	Denominator for diluted net income per share - weighted average shares outstanding - diluted	41,919		41,887		41,771		42,117
	Basic net income per share	$	0.02	$	0.04	$	0.05	$	0.2
	Diluted net income per share	$	0.02	$	0.04	$	0.05	$	0.19

STOCKBASED_COMPENSATION_Tables

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock options activity	'
	The Company’s stock option activity for the nine months ended September 30, 2013 was as follows:
	Stock Options (shares in thousands)	Shares		Weighted Average Exercise Price
	Outstanding at December 31, 2012	1,676		$	12.13
	Granted	159		17.24
	Exercised	(798	)	8.84
	Cancelled or expired	(20	)	19
	Outstanding at September 30, 2013	1,017		$	15.37
Restricted shares activity	'
	The Company’s restricted share activity for the nine months ended September 30, 2013 was as follows:
	Restricted Stock Awards (shares in thousands)	Shares		Weighted Average Grant Price
	Non-vested at December 31, 2012	818		$	19.32
	Granted	354		17.28
	Vested	(265	)	18.83
	Cancelled or expired	(55	)	19.41
	Non-vested at September 30, 2013	852		$	18.62
	Restricted Stock Units (in thousands)	Shares
	Non-vested at December 31, 2012	875
	Granted	193
	Vested	(77	)
	Cancelled or expired	(155	)
	Non-vested at September 30, 2013	836
Stock-based compensation costs recognized in consolidated statements of income	'
	The following are the stock-based compensation costs recognized in the Company’s condensed consolidated statements of comprehensive income (in thousands):
		Three Months Ended September 30,					Nine Months Ended September 30,
		2013			2012		2013		2012
	Cost of revenue	$	233		$	222	$	635	$	697
	Research and development	675			520		1,892		1,507
	Selling, general and administrative	981			1,596		4,206		5,348
	Stock-based compensation costs reflected in net income	$	1,889		$	2,338	$	6,733	$	7,552

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Schedule of segment reporting information by segment	'
	ollowing is selected segment information for the periods indicated (in thousands):
		Three Months Ended September 30, 2013								Three Months Ended September 30, 2012
		TSP Segment		ARP Segment			Consolidated			TSP Segment		ARP Segment			Consolidated
	Revenues from external customers	$	33,335	$	17,445		$	50,780		$	31,584	$	18,463		$	50,047
	Depreciation and amortization	2,087		1,907			$	3,994		1,801		1,812			$	3,613
	Operating profit (loss)	9,293		(13,487		)	$	(4,194	)	7,205		(3,838		)	$	3,367
	Segment assets	187,422		106,474			$	293,896		166,763		115,742			$	282,505
		Nine Months Ended September 30, 2013								Nine Months Ended September 30, 2012
		TSP Segment		ARP Segment			Consolidated			TSP Segment		ARP Segment			Consolidated
	Revenues from external customers	$	96,352	$	61,915		$	158,267		$	91,358	$	55,689		$	147,047
	Depreciation and amortization	5,826		5,921			$	11,747		5,096		5,572			$	10,668
	Operating profit (loss)	23,368		(24,073		)	$	(705	)	21,725		(6,264		)	$	15,461
	Segment assets	187,422		106,474			$	293,896		166,763		115,742			$	282,505

ACCRUED_WARRANTY_COSTS_Tables

ACCRUED WARRANTY COSTS (Tables)	9 Months Ended
	Sep. 30, 2013
Product Warranties Disclosures [Abstract]	'
Changes in warranty accrual	'
	The following table summarizes the changes in the warranty accrual (in thousands):
	Accrued warranty costs at December 31, 2012	$	603
	Warranty expenses	(783		)
	Accrual for warranty costs	1,163
	Accrued warranty costs at September 30, 2013	$	983

BASIS_OF_PRESENTATION_Details

BASIS OF PRESENTATION (Details) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013
Variable Interest Entity [Line Items]	'	'
Number of segments for financial reporting purposes (in number of segments)	2	2
Research and development | Assays and Related Products [Member]	'	'
Variable Interest Entity [Line Items]	'	'
Prior Period Reclassification Adjustment	$0.50	$1.70
Selling, General and Administrative Expenses [Member] | Assays and Related Products [Member]	'	'
Variable Interest Entity [Line Items]	'	'
Prior Period Reclassification Adjustment	$3	$8.90

RESTRUCTURING_Details

RESTRUCTURING (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Restructuring Cost and Reserve [Line Items]	'
Employee Separation Costs	$598
Facility Exit Costs	0
Other Restructuring Costs	50
Total Restructuring Charges	4,343
Restructuring Charges Included In Cost Of Revenue	2,201
Restructuring Charges And Associated Cost	2,142
Asset Impairment Charges	-3,695
Employee Separation Payments	-488
Foreign Exchange and Other Adjustments	-50
Restructuring Reserve	110
Restructuring and Related Cost, Number of Positions Eliminated, Percent	5.00%
Inventories [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Asset Impairment Charges	-2,015
Property, Plant and Equipment [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Asset Impairment Charges	-980
Intangible assets (restructuring) [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Asset Impairment Charges	($700)

BUSINESS_COMBINATIONS_Details

BUSINESS COMBINATIONS (Details) (Business Acquisition - GenturaDx (British Virgin Islands) [Member], USD $)	0 Months Ended
In Millions, unless otherwise specified	Jul. 11, 2012	Sep. 30, 2013
Business Acquisition [Line Items]	'	'
Cash consideration	$49.30	'
Business acquisition, amount of purchase price deposited in escrow	8.1	'
Business acquisition, amount of purchase price remaining in escrow	'	6
Percentage of milestone payments for indemnification claims	'	30.00%
Future Development and Regulatory Milestone Dec 2013 [Member]	'	'
Business Acquisition [Line Items]	'	'
Busines Combination, Contingent Consideration,Potential Cash Payment	3	'
Future Development and Regulatory Milestone June 2014 [Member]	'	'
Business Acquisition [Line Items]	'	'
Busines Combination, Contingent Consideration,Potential Cash Payment	$7	'

INVESTMENTS_Details

INVESTMENTS (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

Money Market Funds [Member]

Money Market Funds [Member]

Current Non-Government Sponsored Debt Securities [Member]

Current Non-Government Sponsored Debt Securities [Member]

Total Current Available-for-sale Securities [Member]

Total Current Available-for-sale Securities [Member]

Non-Current Non-Government Sponsored Debt Securities [Member]

Non-Current Non-Government Sponsored Debt Securities [Member]

Total Non-Current Available-for-sale Securities [Member]

Total Non-Current Available-for-sale Securities [Member]

Investment in Private Company 1 [Member]

Investment in Private Company 1 [Member]

Investment in Private Company 2 [Member]

Components of Available-for-sale Securities [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortized Cost

$41,809,000

'

$41,809,000

$33,589,000

$36,311,000

$16,987,000

$5,498,000

$13,602,000

$41,809,000

$30,589,000

$0

$3,000,000

$0

$3,000,000

'

'

'

Gains in Accumulated Other Comprehensive Gain

'

'

0

5,000

0

0

0

5,000

0

5,000

0

0

0

0

'

'

'

Losses in Accumulated Other Comprehensive Gain

'

'

-1,000

0

0

0

-1,000

0

-1,000

0

0

0

0

0

'

'

'

Estimated Fair Value

41,808,000

'

41,808,000

33,594,000

36,311,000

16,987,000

5,497,000

13,607,000

41,808,000

30,594,000

0

3,000,000

0

3,000,000

'

'

'

Available-for-sale Securities [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from sales of available-for-sale-securities

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net unrealized holding gain (loss) on available-for-sale securities

-1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Tax expense on net unrealized holding gains on available-for-sale securities included in accumulated other comprehensive income

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-sale securities, debt maturities [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Due in one year or less

5,497,000

'

5,497,000

13,607,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Due after one year through two years

0

'

0

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Total estimated fair value of available-for-sale debt securities

5,497,000

'

5,497,000

16,607,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of investments in a private company

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,100,000

1,000,000

Ownership percentage in cost method investment

20.00%

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,400,000

'

'

INVENTORY_NET_Details

INVENTORY, NET (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory, Net [Abstract]	'	'
Parts and supplies	$16,668	$18,259
Work-in-progress	5,928	4,831
Finished goods	7,146	6,847
Inventory, net	$29,742	$29,937

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2012
Amounts included in asset accounts [Abstract]	'	'	'
Money Market funds	$36,311,000	'	$16,987,000
Non-government sponsored debt securities	5,497,000	'	16,607,000
Amounts included in liability accounts [Abstract]	'	'	'
Contingent consideration	0	1,200,000	1,370,000
Long-term debt	1,500,000	'	2,500,000
Fair Value, Inputs, Level 1 [Member]	'	'	'
Amounts included in asset accounts [Abstract]	'	'	'
Money Market funds	36,311,000	'	16,987,000
Non-government sponsored debt securities	0	'	0
Amounts included in liability accounts [Abstract]	'	'	'
Contingent consideration	0	'	0
Fair Value, Inputs, Level 2 [Member]	'	'	'
Amounts included in asset accounts [Abstract]	'	'	'
Money Market funds	0	'	0
Non-government sponsored debt securities	5,497,000	'	16,607,000
Amounts included in liability accounts [Abstract]	'	'	'
Contingent consideration	0	'	0
Fair Value, Inputs, Level 3 [Member]	'	'	'
Amounts included in asset accounts [Abstract]	'	'	'
Money Market funds	0	'	0
Non-government sponsored debt securities	0	'	0
Amounts included in liability accounts [Abstract]	'	'	'
Contingent consideration	$0	'	$1,370,000

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 1) (Fair Value, Inputs, Level 3 [Member], USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Balance at beginning of year	$1,370	$0
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	0	1,370
Fair value adjustments	-1,370	0
Balance at end of period	$0	$1,370

GOODWILL_AND_OTHER_INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Jul. 11, 2012
Intangible Assets [Line Items]	'	'	'	'	'	'
Business acquisition, goodwill	'	'	'	'	'	$8,300,000
Business acquisition, amortizable intangible assets	'	'	'	'	'	40,100,000
Goodwill [Roll Forward]	'	'	'	'	'	'
Balance at beginning of year	'	'	51,128,000	42,763,000	42,763,000	'
Acquisition of GenturaDx	'	'	0	'	8,292,000	'
Foreign currency translation adjustments	'	'	-275,000	'	73,000	'
Balance at end of period	50,853,000	'	50,853,000	'	51,128,000	'
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'	'	'	'
Balance, beginning	'	'	80,584,000	40,545,000	40,545,000	'
Additions due to Acquisition of GenturaDx	'	'	'	'	40,100,000	'
Write Off Of In Process Research And Development Projects	'	'	-700,000	'	-118,000	'
Foreign currency translation adjustments	'	'	-221,000	'	57,000	'
Balance, ending	79,663,000	'	79,663,000	'	80,584,000	'
Less: accumulated amortization [Abstract]	'	'	'	'	'	'
Accumulated amortization, beginning balance	'	'	-15,366,000	-11,108,000	-11,108,000	'
Amortization expense	-1,021,000	-1,030,000	-3,077,000	-3,214,000	-4,243,000	'
Foreign currency translation adjustments	100,000	'	100,000	'	-15,000	'
Accumulated amortization, ending balance	-18,343,000	'	-18,343,000	'	-15,366,000	'
Net balance	61,320,000	'	61,320,000	'	65,218,000	'
Estimated aggregate amortization expense for the next five years and thereafter [Abstract]	'	'	'	'	'	'
2013 (three months)	1,019,000	'	1,019,000	'	'	'
2014	3,917,000	'	3,917,000	'	'	'
2015	3,232,000	'	3,232,000	'	'	'
2016	3,100,000	'	3,100,000	'	'	'
2017	2,144,000	'	2,144,000	'	'	'
Thereafter	7,808,000	'	7,808,000	'	'	'
Total	21,220,000	'	21,220,000	'	'	'
IP R&D	40,100,000	'	40,100,000	'	'	'
Total	61,320,000	'	61,320,000	'	'	'
In-process Research and Development [Member]	'	'	'	'	'	'
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'	'	'	'
Balance, beginning	'	'	40,627,000	631,000	631,000	'
Additions due to Acquisition of GenturaDx	'	'	'	'	40,100,000	'
Write Off Of In Process Research And Development Projects	'	'	-459,000	'	-118,000	'
Foreign currency translation adjustments	'	'	-68,000	'	14,000	'
Balance, ending	40,100,000	'	40,100,000	'	40,627,000	'
Less: accumulated amortization [Abstract]	'	'	'	'	'	'
Accumulated amortization, beginning balance	'	'	0	0	0	'
Amortization expense	'	'	0	'	0	'
Foreign currency translation adjustments	0	'	0	'	0	'
Accumulated amortization, ending balance	0	'	0	'	0	'
Net balance	40,100,000	'	40,100,000	'	40,627,000	'
Technology, Trade Secrets, and Know-how [Member]	'	'	'	'	'	'
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'	'	'	'
Balance, beginning	'	'	30,030,000	30,000,000	30,000,000	'
Additions due to Acquisition of GenturaDx	'	'	'	'	0	'
Write Off Of In Process Research And Development Projects	'	'	-214,000	'	0	'
Foreign currency translation adjustments	'	'	-105,000	'	30,000	'
Balance, ending	29,711,000	'	29,711,000	'	30,030,000	'
Less: accumulated amortization [Abstract]	'	'	'	'	'	'
Accumulated amortization, beginning balance	'	'	-13,193,000	-9,999,000	-9,999,000	'
Amortization expense	'	'	-2,381,000	'	-3,187,000	'
Foreign currency translation adjustments	61,000	'	61,000	'	-7,000	'
Accumulated amortization, ending balance	-15,513,000	'	-15,513,000	'	-13,193,000	'
Net balance	14,198,000	'	14,198,000	'	16,837,000	'
Weighted average life (in years)	'	'	'10 years	'	'10 years	'
Customer Lists and Contracts [Member]	'	'	'	'	'	'
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'	'	'	'
Balance, beginning	'	'	7,986,000	7,981,000	7,981,000	'
Additions due to Acquisition of GenturaDx	'	'	'	'	0	'
Write Off Of In Process Research And Development Projects	'	'	-7,000	'	0	'
Foreign currency translation adjustments	'	'	-19,000	'	5,000	'
Balance, ending	7,960,000	'	7,960,000	'	7,986,000	'
Less: accumulated amortization [Abstract]	'	'	'	'	'	'
Accumulated amortization, beginning balance	'	'	-1,560,000	-768,000	-768,000	'
Amortization expense	'	'	-591,000	'	-790,000	'
Foreign currency translation adjustments	14,000	'	14,000	'	-2,000	'
Accumulated amortization, ending balance	-2,137,000	'	-2,137,000	'	-1,560,000	'
Net balance	5,823,000	'	5,823,000	'	6,426,000	'
Weighted average life (in years)	'	'	'11 years	'	'11 years	'
Other Identifiable Intangible Assets [Member]	'	'	'	'	'	'
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'	'	'	'
Balance, beginning	'	'	1,941,000	1,933,000	1,933,000	'
Additions due to Acquisition of GenturaDx	'	'	'	'	0	'
Write Off Of In Process Research And Development Projects	'	'	-20,000	'	0	'
Foreign currency translation adjustments	'	'	-29,000	'	8,000	'
Balance, ending	1,892,000	'	1,892,000	'	1,941,000	'
Less: accumulated amortization [Abstract]	'	'	'	'	'	'
Accumulated amortization, beginning balance	'	'	-613,000	-341,000	-341,000	'
Amortization expense	'	'	-105,000	'	-266,000	'
Foreign currency translation adjustments	25,000	'	25,000	'	-6,000	'
Accumulated amortization, ending balance	-693,000	'	-693,000	'	-613,000	'
Net balance	1,199,000	'	1,199,000	'	1,328,000	'
Weighted average life (in years)	'	'	'9 years	'	'9 years	'
Minimum [Member]	'	'	'	'	'	'
Intangible Assets [Line Items]	'	'	'	'	'	'
Research and Development Expense, Estimated	'	'	7,000,000	'	'	'
Maximum [Member]	'	'	'	'	'	'
Intangible Assets [Line Items]	'	'	'	'	'	'
Research and Development Expense, Estimated	'	'	$10,000,000	'	'	'

OTHER_COMPREHENSIVE_LOSS_INCOM2

OTHER COMPREHENSIVE (LOSS) INCOME (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'	'
Beginning balance, December 31, 2012	'	'	$1,101	'
Other comprehensive (loss) income before reclassifications	'	'	-507	'
Amounts reclassified from accumulated other comprehensive income	'	'	-9	'
Net current-period other comprehensive (loss)	107	264	-516	176
Ending balance, September 30, 2013	585	'	585	'
Available-for-sale Securities [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'	'
Beginning balance, December 31, 2012	'	'	1	'
Other comprehensive (loss) income before reclassifications	'	'	8	'
Amounts reclassified from accumulated other comprehensive income	'	'	-9	'
Net current-period other comprehensive (loss)	'	'	-1	'
Ending balance, September 30, 2013	0	'	0	'
Accumulated Translation Adjustment [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'	'
Beginning balance, December 31, 2012	'	'	1,100	'
Other comprehensive (loss) income before reclassifications	'	'	-515	'
Amounts reclassified from accumulated other comprehensive income	'	'	0	'
Net current-period other comprehensive (loss)	'	'	-515	'
Ending balance, September 30, 2013	$585	'	$585	'

OTHER_COMPREHENSIVE_LOSS_INCOM3

OTHER COMPREHENSIVE (LOSS) INCOME (Details 1) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'	'
Foreign currency translation adjustments, before tax	$106	'	($515)	'
Foreign currency translation adjustments, tax benefit	0	'	0	'
Foreign currency translation adjustments, net of tax	106	'	-515	'
Unrealized gains on available-for-sale investments, before tax	1	'	-2	'
Unrealized gains on available-for-sale investments, tax benefit	0	'	1	'
Unrealized gains on available-for-sale investments, net of tax	1	'	-1	'
Other comprehensive (loss) income, before tax	107	'	-517	'
Other comprehensive (loss) income, tax benefit	0	'	1	'
Other comprehensive (loss) income, net of tax	$107	$264	($516)	$176

EARNINGS_PER_SHARE_Details

EARNINGS PER SHARE (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator:	'	'	'	'
Net income	$796	$1,676	$1,980	$8,155
Denominator:	'	'	'	'
Denominator for basic net income per share - weighted average common stock outstanding	40,752	41,000	40,712	40,995
Effect of dilutive securities: stock options and awards	1,167	887	1,059	1,122
Denominator for diluted net income per share - weighted average shares outstanding - diluted	41,919	41,887	41,771	42,117
Basic net income per share	$0.02	$0.04	$0.05	$0.20
Diluted net income per share	$0.02	$0.04	$0.05	$0.19
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive restricted stock awards, stock options	189	207	189	207

STOCKBASED_COMPENSATION_Detail

STOCK-BASED COMPENSATION (Details) (USD $)	9 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Sep. 30, 2013
Stock options, additional Disclosures [Abstract]	'
Total unrecognized compensation costs	$2.30
Unrecognized compensation costs, weighted average period of recognition (in years)	'1 year 10 months 28 days
Stock Options [Member]	'
Stock options, outstanding [Roll Forward]	'
Options outstanding, beginning balance (in shares)	1,676
Granted (in shares)	159
Exercised (in shares)	-798
Cancelled or expired (in shares)	-20
Options outstanding, ending balance (in shares)	1,017
Stock options, additional Disclosures [Abstract]	'
Weighted-average price, beginning of period (in dollars per share)	$12.13
Weighted-average price, granted (in dollars per share)	$17.24
Weighted average price, exercised (in dollars per share)	$8.84
Weighted-average price, cancelled or expired (in dollars per share)	$19
Weighted-average price, end of period (in dollars per share)	$15.37
Restricted Stock [Member]	'
Stock options, additional Disclosures [Abstract]	'
Total unrecognized compensation costs	15.1
Unrecognized compensation costs, weighted average period of recognition (in years)	'3 years 1 month 28 days
Equity instruments other than options, nonvested [Roll Forward]	'
Non-vested, beginning balance (in shares)	818
Granted (in shares)	354
Vested (in shares)	-265
Cancelled or expired (in shares)	-55
Non-vested, ending balance (in shares)	852
Equity instruments other than options, additional Disclosures [Abstract]	'
Non-vested, beginning balance (in dollars per share)	$19.32
Granted (in dollars per share)	$17.28
Vested (in dollars per share)	$18.83
Cancelled or expired (in dollars per share)	$19.41
Non-vested, ending balance (in dollars per share)	$18.62
Restricted Stock Units (RSUs) [Member]	'
Stock options, additional Disclosures [Abstract]	'
Total unrecognized compensation costs	$5.30
Unrecognized compensation costs, weighted average period of recognition (in years)	'2 years 2 months 5 days
Equity instruments other than options, nonvested [Roll Forward]	'
Non-vested, beginning balance (in shares)	875
Granted (in shares)	193
Vested (in shares)	-77
Cancelled or expired (in shares)	-155
Non-vested, ending balance (in shares)	836

STOCKBASED_COMPENSATION_Detail1

STOCK-BASED COMPENSATION (Details 1) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Cost of revenue	'	'	'	'
Share-based Compensation, allocation and classification in income statements [Abstract]	'	'	'	'
Stock-based compensation costs	$233	$222	$635	$697
Research and development	'	'	'	'
Share-based Compensation, allocation and classification in income statements [Abstract]	'	'	'	'
Stock-based compensation costs	675	520	1,892	1,507
Selling, general and administrative	'	'	'	'
Share-based Compensation, allocation and classification in income statements [Abstract]	'	'	'	'
Stock-based compensation costs	981	1,596	4,206	5,348
Selling, general and administrative	'	'	'	'
Share-based Compensation, allocation and classification in income statements [Abstract]	'	'	'	'
Stock-based compensation costs	$1,889	$2,338	$6,733	$7,552

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Segment Reporting [Abstract]	'	'	'	'	'
Number of segments (in number of segments)	2	'	2	'	'
Intersegment sales	$2,200,000	$2,500,000	$7,900,000	$8,200,000	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues from external customers	50,780,000	50,047,000	158,267,000	147,047,000	'
Depreciation and amortization	3,994,000	3,613,000	11,747,000	10,668,000	'
Operating profit (loss)	-4,194,000	3,367,000	-705,000	15,461,000	'
Assets	293,896,000	282,505,000	293,896,000	282,505,000	297,175,000
Technology and Strategic Partnerships [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues from external customers	33,335,000	31,584,000	96,352,000	91,358,000	'
Depreciation and amortization	2,087,000	1,801,000	5,826,000	5,096,000	'
Operating profit (loss)	9,293,000	7,205,000	23,368,000	21,725,000	'
Assets	187,422,000	166,763,000	187,422,000	166,763,000	'
Assays and Related Products [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenues from external customers	17,445,000	18,463,000	61,915,000	55,689,000	'
Depreciation and amortization	1,907,000	1,812,000	5,921,000	5,572,000	'
Operating profit (loss)	-13,487,000	-3,838,000	-24,073,000	-6,264,000	'
Assets	$106,474,000	$115,742,000	$106,474,000	$115,742,000	'

ACCRUED_WARRANTY_COSTS_Details

ACCRUED WARRANTY COSTS (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Accrued warranty costs [Roll Forward]	'
Accrued warranty costs at December 31, 2012	$603
Warranty expenses	-783
Accrual for warranty costs	1,163
Accrued warranty costs at September 30, 2013	$983

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'	'
Effective tax rate, including amounts recorded for discrete events (in hundredths)	'	66.77%
Statutory rate (in hundredths)	'	35.00%
Minimum rate for cash taxes expected to be paid (in hundredths)	'	15.00%
Maximum rate for cash taxes expected to be paid (in hundredths)	'	20.00%
Liability associated with its uncertain tax position	$121,000	'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Distribution Agreement Settlement Expense	$7